Episode Details

Two healthcare biotechs, Moderna and Abivax, are poised for potential outperformance in the next five years. Modernas mRNA-four one five seven vaccine, when combined with Mercks Keytruda, showed promising results in a phase two trial for various cancers. Abivax, a French company, is developing obefazimod for ulcerative colitis, which could potentially outperform rivals without their side effects. Both companies face clinical challenges, but their pipelines position them for strong runs if trials succeed, making them attractive options for bold investors seeking growth amid market jitters.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/6810c81b43133f1c